Drugs / TR64
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05649345 | Jan 2023 → Aug 2026 overdue | — | Tarapeutics Science Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TR64 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05649345 ↗ |
| Route | Oral | “Daily doses by oral administration on each day of each 28 day cycle.” NCT05649345 ↗ |